: iStockAnalyst.com Symbols Feed

Big Pharma And Biotech - Industry Outlook

Mon, 09 Nov 2009 21:58:02 GMT

The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses.[More...]

More New 2009 Highs!

Tue, 20 Oct 2009 00:22:50 GMT

The market started the week with another gain. However they started out weaker and immediately tested initial support that held. When that occurred they turned around and rallied very sharply, with the NDX rallying from 1732 to 1758, 26 points in 2 hours. The SPX rallied from 1086 to 1099 during that time frame.[More...]

This Fall Will Be Crazy For These Biotech Stocks

Fri, 16 Oct 2009 18:50:27 GMT

Most speculators have it all wrong when it comes to biotech trading... They'll buy biotech stocks ahead of FDA decisions, hoping an approval will bring 100% overnight gains. But more often than not, the market is one step ahead. The stock price will creep up as everyone anticipates good news.[More...]

Blue Chips Continue Rally, But Nasdaq 100 Lags

Thu, 15 Oct 2009 22:23:46 GMT

The indices managed to squeeze out a gain on the blue chips, but the Nasdaq 100 was down a very small fraction and the Philadelphia Semiconductor Index (SOXX) got hit for more than 1%, so it was a mixed close.[More...]

A Positive FDA Panel Outcome for Acorda Therapeutics (NASDAQ: ACOR)

Thu, 15 Oct 2009 14:19:20 GMT

On 4/23/09, Acorda Therapeutics (NASDAQ: ACOR) announced the resubmission of its NDA for Fampridine-SR (Amaya) to the FDA as a new therapy being developed to improve walking ability in people with multiple sclerosis (MS) in response to a Refuse to File letter for the NDA issued by the Agency in late March. On 5/6/09, the FDA accepted the NDA with a priority review (six-month review) designation and a PDUFA action date of 10/22/09 as there are currently no FDA approved treatments[More...]

FDA Calendar Updates: Acorda, Amgen, DOR BioPharma

Tue, 04 Aug 2009 18:26:21 GMT

Below is a summary of updates to the BioMedReports.com FDA Calendar, which includes a database of 290 entries as of 8/4/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, ANDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete (...)[More...]

FDA Calendar Updates: ACOR, HGSI, RPRX, Pharming

Wed, 01 Jul 2009 21:39:00 GMT

Below is a summary of updates to the BioMedReports.com FDA Calendar, which includes a database of over 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response lette (...)[More...]

ACOR & BIIB Team Up On MS Drug

Wed, 01 Jul 2009 20:32:18 GMT

This morning, Acorda Therapeutics (ACOR) announced that it has entered into an exclusive collaboration and licensing agreement to develop and commercialize Fampridine-SR, the company's therapy to improve walking ability in patients with multiple sclerosis (MS), with Biogen Idec (BIIB) for territories outside the U.S. These territories include Europe, Canada and Australia, among others, and relate to all current and future aminopyridine products. Biogen will pay Acorda an upfront payment of $110 million in cash as part of the transaction. Acorda can earn an additional $400 million in regulatory and sales related milestones, plus a tiered double-digit royalty on sales of the drug.[More...]

Pharmaceuticals & Biotech - Industry Outlook

Tue, 09 Jun 2009 12:05:35 GMT

The pharmaceutical industry is entering a period of substantial change in 2009. Most of the names in the industry are facing significant patent challenges in the years to come. U.S.-based firms are facing foreign exchange headwinds, as well. Revenue growth is non-existent, and earnings growth is being driven primarily by mergers, cost-cutting and share buybacks. Knowing that investors rarely pay-up for this type of manufactured earnings growth, we struggle to see a broad-based out-performance for the large-cap pharmaceutical sector in 2009. Valuations, however, are attractive, with several of the largest players trading at PEs below 10x, including: Pfizer (PFE, 7.5x), Eli Lilly (LLY,[More...]

The Meek Continue To Dominate Equities

Mon, 27 Apr 2009 05:49:10 GMT

Early in April after a month long run off the bottom I posted a list of equities that gained at least 60% in the preceding 4 weeks (Apr 5: The Meek Shall Inherit the Earth: 92 Stocks Over $10 Returning 60%+) The list was a whose who of beaten down merchandise. Generally, by week 4-5 of an oversold rally these type of names begin to peter out but the ramp has been relentless in lower quality, low price stocks. My gut tells me quant (and other varieties) of hedge funds have been shorting these names, using fundamental reasons - expecting some pullback after huge runs - only to be run over again and again even in week 6 and 7 of this rally. All it takes nowadays is saying "business has stabilized at the worst levels we've seen in decades" to elicit glee and massive short covering rallies. While the market was flattish last week, I[More...]

Citigroup, Nokia, Capital 1, Safeway big movers

Thu, 15 Oct 2009 23:05:00 GMT

NEW YORK - The following stocks were among those that moved substantially or traded heavily Thursday on the New York Stock Exchange:
The bank reported that its disappointing third-quarter results were weighed down by billions of dollars in failed loans.
The mobile phone maker posted a third-quarter loss on a drop in sales and a charge for the fallen value of its network equipment unit.

: iStockAnalyst.com Symbols Feed

Big Pharma And Biotech - Industry Outlook

More New 2009 Highs!

This Fall Will Be Crazy For These Biotech Stocks

Blue Chips Continue Rally, But Nasdaq 100 Lags

A Positive FDA Panel Outcome for Acorda Therapeutics (NASDAQ: ACOR)

FDA Calendar Updates: Acorda, Amgen, DOR BioPharma

FDA Calendar Updates: ACOR, HGSI, RPRX, Pharming

ACOR & BIIB Team Up On MS Drug

Pharmaceuticals & Biotech - Industry Outlook

The Meek Continue To Dominate Equities

Citigroup, Nokia, Capital 1, Safeway big movers

Biogen Idec: Shifting Its Multiple Sclerosis Pipeline

AIG, General Mills, MetroPCS are big movers

Acorda shares fall on Biogen partnership

Acorda Therapeutics Reports Third Quarter 2009 Financial Results

PicksThatMove.Com Announces Investment Opinion Hot Stocks on NVNC, MPG, ACOR, KNA and ROYL

Acorda Therapeutics Names Ruhi Kahn as Vice President, Business Development

Acorda Therapeutics Reports Second Quarter 2009 Financial Results

Acorda Therapeutics to Host Conference Call to Report Second Quarter 2009 Financial Results on August 4, 2009

Biogen Idec Reports Second Quarter 2009 Results

Biogen Idec and Acorda Therapeutics Announce Collaboration Agreement to Develop and Commercialize MS Therapy Fampridine-SR in Markets Outside the U.S.

Acorda Therapeutics Announces Eligibility of Fampridine-SR for Centralized Review in Europe

Acorda Therapeutics Reports First Quarter 2009 Financial Results

Acorda Therapeutics Announces FDA Acceptance of Fampridine-SR New Drug Application for Filing

Form 4 ACORDA THERAPEUTICS INC For: Dec 01 Filed by: LAWRENCE DAVID (10K)

Form 4 ACORDA THERAPEUTICS INC For: Dec 01 Filed by: Blight Andrew (10K)

Form 4 ACORDA THERAPEUTICS INC For: Aug 12 Filed by: Randall Lorin (10K)

Form 4 ACORDA THERAPEUTICS INC For: Jun 22 Filed by: YOUNG WISE (10K)

Form 4 SMITH IAN F For: Jun 22 (10K)

Form 4 ACORDA THERAPEUTICS INC For: Jun 22 Filed by: PANEM SANDRA PHD (10K)

Form 4 ACORDA THERAPEUTICS INC For: Jun 22 Filed by: Randall Lorin (10K)

Form 4 ACORDA THERAPEUTICS INC For: Jun 22 Filed by: Kelley John P (10K)

Form 4 ACORDA THERAPEUTICS INC For: Jun 22 Filed by: Greene Barry E (10K)

Form 4 ACORDA THERAPEUTICS INC For: Mar 02 Filed by: LAWRENCE DAVID (10K)